【摘要】 目的:评价喹硫平联合抗抑郁剂对治疗反应不佳的抑郁症的临床疗效和安全性。方法:对75例单一抗抑郁剂治疗无效或部分反应的抑郁症患者随机纳入加用喹硫平或保持原治疗方案组,共观察6周,使用汉密尔顿抑郁量表(HAMD-17)评价疗效,并观察不良反应。结果:喹硫平组和观察组分别脱落7例及5例,可供分析病例63例。结果显示试验终点喹硫平组(n=31)和观察组(n=32)HAMD-17减分分别为-(12.6±5.7)和-(6.7±6.1)分(P<0.01),有效率和缓解率分别为61%,28%(P<0.01)及39%、16%(P<0.05),喹硫平组在治疗的第2周开始出现增效作用;喹硫平组头昏、食欲增加较多,观察组失眠及恶心较多见。结论:喹硫平联合抗抑郁剂治疗抑郁症可增加疗效,不良反应并未明显增多,增效作用较快,适合于治疗对单一抗抑郁剂治疗部分有效或未能缓解的抑郁症患者。更多还原

【Abstract】 OBJECTIVE To evaluate whether or not augmentation with quetiapine is beneficial and safe to patients with an inadequate response to antidepressants.METHODS 75 patients with an inadequate response to one antidepressant were assigned randomly to either of quetiapine plus ongoing antidepressant group or antidepressant alone group for 6 weeks,and changes from baseline in the Hamilton Rating Scale for Depression(HAMD-17)total score of two groups and adverse events were compared.RESULTS 63 patients completed the trial.Mean changes for HAMD from baseline to week 6 were 12.6±5.7(quetiapine,n=31)and-6.7±6.1(antidepressant alone,n=32)(P<0.01),the responding and remission rate was 61% vs 28%(P<0.01)and 39% vs 16%(P<0.05)separately,Augmentation with quetiapine was well tolerated,as for treatment-emergent adverse events,there was more dizziness and increased food appetite for quetiapine group,and more insomnia and nausea for quetiapine group.CONCLUSION The results indicate that quetiapine may be a useful and safe adjunct to antidepressant for depressive patients with an inadequate response to antidepressants.更多还原